Skip to content
ENT SurgicalTech & Protocols

Facial Nerve Monitoring in Canal Wall Up Mastoidectomy and Tympanoplasty: Threshold-Guided Facial Recess Access

Stimulus thresholds drop from 0.66 mA to 0.32 mA after facial recess opening, enabling wider posterior tympanotomy access without facial nerve injury.

IP

Editorial Team

Clinical evidence review

7 min read
Source:Chinese Journal of Otology (2014)DOI10.3969/j.issn.1672-2922.2014.04.020

Key Takeaways

  • Stimulus thresholds at the facial nerve mastoid segment fell from 0.66 ± 0.16 mA (range 0.38–0.90 mA) before facial recess opening to 0.32 ± 0.09 mA (range 0.16–0.43 mA) after opening (paired t-test, p < 0.05), providing a quantitative endpoint for safe posterior tympanotomy.
  • No immediate or delayed facial palsy occurred in any of the 21 completed canal wall up (CWU) procedures, despite deliberate widening of the facial recess window for complete posterior tympanum clearance.
  • Facial canal dehiscence was identified intraoperatively in 4 of 21 cases (19.0%), with exposed nerve thresholds of 0.08–0.22 mA; one additional case of anteriorly displaced facial nerve was detected by monitoring and converted to an open technique.
  • A threshold ≤ 0.40 mA signals thin residual bone or frank dehiscence and should prompt cessation of drilling, confirmatory mapping, and consideration of endoscopic-assisted clearance or conversion to an open approach.

Clinical Context

Canal wall up mastoidectomy with tympanoplasty preserves the posterior external auditory canal wall and the normal anatomy and physiology of the middle ear, avoiding the chronic "mastoid cavity problem" of discharge, hearing decline, vestibular disturbance, and tinnitus associated with open cavity surgery. Its principal liabilities are residual disease and recurrence, particularly in the posterior tympanum, epitympanum, and perifacial regions — sites where complete clearance demands maximal enlargement of the facial recess.

The facial recess is a triangular corridor bounded superiorly by the incus fossa, laterally by the chorda tympani, and medially by the upper mastoid segment of the facial nerve. Widening this window brings the drill and dissection instruments into immediate proximity to the facial nerve, whose bony covering may be congenitally dehiscent or altered by chronic inflammation, mucosal edema, granulation tissue, or cholesteatoma. Published microscopic series report facial canal dehiscence in up to 43% of operated ears, and monitoring-confirmed anomalous facial nerve course in approximately 1.5% of cases. Anatomic landmark identification alone therefore carries a meaningful risk of iatrogenic facial palsy.

This article distills a consecutive single-surgeon experience from a high-volume tertiary otology practice into a practical, threshold-driven IONM protocol for CWU surgery.

Clinical Evidence & Cohort Breakdown

Twenty-four patients with chronic suppurative otitis media were scheduled for CWU tympanoplasty based on preoperative endoscopy, pure-tone audiometry, eustachian tube function, and high-resolution temporal bone CT (pneumatic or diploic mastoid, localized disease judged completely resectable, competent eustachian tube). All patients consented to possible conversion to an open technique. Three cases were converted intraoperatively: two for extensive cholesteatoma precluding complete clearance, and one for monitoring-confirmed anterior displacement of the facial nerve. Twenty-one CWU procedures were completed.

Parameter Value
Completed CWU procedures 21 (of 24 planned)
Sex distribution 13 male / 8 female
Age, mean (range) 32.19 years (14–46)
Disease duration, mean (range) 10.02 years (0.5–30)
Side 11 right / 10 left
Cholesteatoma present 11 cases
Conversions to open technique 3 (2 extensive cholesteatoma, 1 anteriorly displaced FN)
FN mastoid segment threshold, before facial recess opening 0.38–0.90 mA; mean 0.66 ± 0.16 mA
FN mastoid segment threshold, after facial recess opening 0.16–0.43 mA; mean 0.32 ± 0.09 mA
Paired t-test (before vs. after) p < 0.05
Tympanic segment bony dehiscence identified 4 cases (19.0%)
Exposed FN threshold in dehiscence cases 0.08–0.22 mA
Immediate / delayed facial palsy 0 / 21 (0%)
Dry ear at 3 months 95.2% (20/21)
Dry ear at 6 months 100% (21/21)
Mean time to dry ear 28 days (range 21–98)

Two of the four dehiscence cases were associated with cholesteatoma; the remaining two had no adjacent pathological tissue and were considered congenital canal defects. The single delayed dry ear at 3 months was attributable to fungal infection of the operative cavity and resolved by week 14 with intensified dressing care. No recurrence was observed through the 6-month follow-up.

Intraoperative IONM Protocol & Technical Pearls

  1. Anesthesia setup. General endotracheal intubation, with neuromuscular blocking agents withheld immediately after intubation to eliminate neuromuscular blockade (NMB) residual and preserve reliable EMG amplitude responses throughout the case.
  2. Electrode placement. Place subdermal needle electrodes in the ipsilateral frontalis, orbicularis oculi, orbicularis oris, and buccinator muscles. Position the ground electrode at the suprasternal notch and the stimulator anode at the clavicle; secure all leads with a connection box to the monitoring console.
  3. Baseline free-run surveillance. During mastoid contouring and facial recess drilling, treat sustained non-synchronized "click" alarms with non-synchronized response waveforms as a proximity warning — the drill tip is within approximately 1 mm of the facial canal. Pause, reposition, and reduce mechanical, thermal, and traction insult.
  4. Initial electrical mapping (pre-recess). Using a monopolar stimulating probe, begin at 0.80 mA with 1–2 s of effective contact along the anatomically anticipated mastoid segment course. On eliciting a synchronized EMG response with audible "beep," titrate the current downward until the response disappears; record this threshold.
  5. Threshold interpretation. A pre-opening threshold in the 0.38–0.90 mA range is consistent with an intact bony canal of normal thickness. A threshold approaching or below 0.40 mA indicates only a thin bony shell or frank dehiscence — stop drilling and confirm with mapping.
  6. Post-opening endpoint. Once the mastoid segment is faintly visible under the microscope, cease drilling and re-titrate the current to the disappearance threshold. A value near or below 0.40 mA defines satisfactory opening; the observed post-opening mean of 0.32 ± 0.09 mA reflects the intentionally thinned canal wall over the exposed segment.
  7. Dehiscence and soft-tissue discrimination. Where canal defect, exposed nerve, or adherent granulation tissue is suspected, use the probe to differentiate neural from non-neural tissue and record the exposed-nerve threshold (0.08–0.22 mA in this series). Never divide soft tissue over the tympanic segment or geniculate region without monitoring confirmation.
  8. Decision rules for inadequate exposure. If the bone window is too small for complete posterior tympanum clearance at a threshold ≤ 0.40 mA, either supplement with video otoendoscopic inspection of the posterior tympanum and facial recess, or convert to an open technique — do not persist with blind drilling.
  9. Anomalous course. A monitoring-confirmed anteriorly displaced facial nerve that precludes adequate recess exposure is an indication for conversion to canal wall down surgery.
  10. Closure and cavity management. Perform ossiculoplasty according to ossicular status, place negative-pressure drainage of the mastoid cavity for 48 hours, pack the external canal with iodoform gauze, and continue antibiotic therapy for 2 weeks. Schedule follow-up at weeks 2, 3, 4, 6, 8, and 12, with pure-tone audiometry at 3 months.

Clinical Implications for Surgeons & IONM Specialists

  • Monitoring converts a qualitative anatomic judgment into a quantitative surgical endpoint. The stepwise fall in stimulation threshold from a mean of 0.66 mA to 0.32 mA objectively documents progressive bony thinning over the facial nerve, allowing the surgeon to enlarge the facial recess window with confidence rather than by visual estimation alone.
  • A 0.40 mA stop rule is a practical safety trigger. It aligns with previously published recommendations (0.7 mA for initial probing, 0.4 mA as the satisfactory-opening threshold) and with reported exposed-nerve thresholds of 0.08–0.25 mA. Teams should build this cutoff into their institutional protocol.
  • Dehiscence is common and frequently silent. With a 19.0% incidence in this cohort — half without adjacent inflammatory disease — routine mapping of the tympanic segment and geniculate region should be standard, not selective.
  • Monitoring does not replace anatomy. Stimulation is only valid within a limited working distance from the nerve and is degraded by active bleeding; the probe must be used to confirm, not to substitute for, landmark-based dissection.
  • Have a predefined escalation pathway. Endoscopic-assisted posterior tympanum clearance and conversion to an open technique are both legitimate responses to an inadequate window at a low threshold; deciding this in advance prevents both incomplete disease clearance and nerve injury.
  • Limitations. This is a small, single-center series with 6-month follow-up; longer-term recurrence data are needed before drawing conclusions about durability of disease control.

Reference

Ji S, Chen X, Li K, Cai X, Xu Y. Facial Nerve Monitoring during Canal Wall Up Mastoidectomy and Tympanoplasty. Chinese Journal of Otology. 2014;12(4):587-589. DOI: 10.3969/j.issn.1672-2922.2014.04.020

Medical Disclaimer: This article is provided for educational and informational purposes only and does not constitute medical advice. Clinical protocols, stimulation parameters, and surgical decision-making must be individualized to each patient and institution, and readers should consult qualified specialists and current official guidelines before applying any technique described herein.

Medical disclaimer

This protocol is provided for clinical education and reference only. It does not constitute medical advice, a standard of care, or a substitute for surgeon judgment, institutional policy, device labeling, or patient-specific assessment. Verify all stimulation parameters, electrode compatibility and indications against current manufacturer instructions before use. Read the full disclaimer.

Continue the protocol

Related guidance

View the IONM library